Have your own idea? Try our Stock Screener
Chinese (SSE) Life Sciences Industry Analysis
UpdatedApr 12, 2026
DataAggregated Company Financials
Companies27
- 7D5.3%
- 3M-1.4%
- 1Y61.7%
- YTD5.6%
The Life Sciences industry is up 5.3% in the last week, with WuXi AppTec up 6.3%. Meanwhile, Beijing Hotgen Biotech actually underperformed within the industry, shrinking 6.3% in the last week. This means that the industry has gained 62% over the past year. As for the next few years, earnings are expected to grow by 18% per annum.
Industry Valuation and Performance
Has the Chinese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 12 Apr 2026 | CN¥613.9b | CN¥94.9b | CN¥20.7b | 64.5x | 29.6x | 6.5x |
| Tue, 10 Mar 2026 | CN¥550.7b | CN¥94.5b | CN¥18.7b | 60.4x | 29.5x | 5.8x |
| Thu, 05 Feb 2026 | CN¥594.9b | CN¥94.3b | CN¥18.5b | 63.4x | 32.1x | 6.3x |
| Sat, 03 Jan 2026 | CN¥547.6b | CN¥94.3b | CN¥18.5b | 59.6x | 29.6x | 5.8x |
| Mon, 01 Dec 2025 | CN¥549.3b | CN¥94.3b | CN¥18.5b | 65.6x | 29.6x | 5.8x |
| Wed, 29 Oct 2025 | CN¥600.8b | CN¥93.2b | CN¥18.4b | 68.8x | 32.7x | 6.4x |
| Fri, 26 Sep 2025 | CN¥625.7b | CN¥92.1b | CN¥17.4b | 74.8x | 35.9x | 6.8x |
| Sun, 24 Aug 2025 | CN¥586.0b | CN¥92.5b | CN¥17.5b | 61.4x | 33.4x | 6.3x |
| Tue, 22 Jul 2025 | CN¥513.0b | CN¥89.8b | CN¥15.4b | 53.7x | 33.4x | 5.7x |
| Thu, 19 Jun 2025 | CN¥422.5b | CN¥89.8b | CN¥15.4b | 46.9x | 27.5x | 4.7x |
| Sat, 17 May 2025 | CN¥392.6b | CN¥89.6b | CN¥15.5b | 44.9x | 25.4x | 4.4x |
| Mon, 14 Apr 2025 | CN¥367.7b | CN¥88.5b | CN¥14.0b | 38.3x | 26.2x | 4.2x |
| Wed, 12 Mar 2025 | CN¥434.2b | CN¥89.0b | CN¥11.3b | 43.8x | 38.3x | 4.9x |
| Fri, 07 Feb 2025 | CN¥378.5b | CN¥88.1b | CN¥11.2b | 39.2x | 33.7x | 4.3x |
| Sun, 05 Jan 2025 | CN¥347.1b | CN¥87.8b | CN¥11.2b | 34.2x | 31x | 4x |
| Tue, 03 Dec 2024 | CN¥374.4b | CN¥87.8b | CN¥11.2b | 39.9x | 33.5x | 4.3x |
| Thu, 31 Oct 2024 | CN¥372.6b | CN¥88.3b | CN¥11.5b | 37.1x | 32.3x | 4.2x |
| Sat, 28 Sep 2024 | CN¥333.6b | CN¥88.2b | CN¥12.4b | 31.1x | 27x | 3.8x |
| Mon, 26 Aug 2024 | CN¥262.3b | CN¥87.4b | CN¥12.3b | 23.8x | 21.3x | 3x |
| Wed, 24 Jul 2024 | CN¥282.6b | CN¥88.3b | CN¥13.4b | 26.9x | 21.1x | 3.2x |
| Fri, 21 Jun 2024 | CN¥294.8b | CN¥88.3b | CN¥13.4b | 26.1x | 22x | 3.3x |
| Sun, 19 May 2024 | CN¥330.3b | CN¥88.3b | CN¥13.3b | 29.1x | 24.8x | 3.7x |
| Tue, 16 Apr 2024 | CN¥316.6b | CN¥90.3b | CN¥15.0b | 31.7x | 21.1x | 3.5x |
| Thu, 14 Mar 2024 | CN¥373.4b | CN¥90.5b | CN¥15.5b | 32.7x | 24.1x | 4.1x |
| Sat, 10 Feb 2024 | CN¥349.1b | CN¥91.1b | CN¥16.1b | 29.9x | 21.7x | 3.8x |
| Mon, 08 Jan 2024 | CN¥448.6b | CN¥91.1b | CN¥16.1b | 37.1x | 27.9x | 4.9x |
| Wed, 06 Dec 2023 | CN¥492.7b | CN¥91.1b | CN¥16.1b | 36.8x | 30.6x | 5.4x |
| Fri, 03 Nov 2023 | CN¥530.3b | CN¥91.1b | CN¥16.1b | 37.8x | 32.9x | 5.8x |
| Sun, 01 Oct 2023 | CN¥520.4b | CN¥92.0b | CN¥18.3b | 35.6x | 28.4x | 5.7x |
| Tue, 29 Aug 2023 | CN¥486.2b | CN¥92.2b | CN¥18.8b | 33.6x | 25.9x | 5.3x |
| Thu, 27 Jul 2023 | CN¥469.7b | CN¥91.3b | CN¥18.5b | 34.2x | 25.4x | 5.1x |
| Sat, 24 Jun 2023 | CN¥454.7b | CN¥91.3b | CN¥18.5b | 33.9x | 24.6x | 5x |
| Mon, 22 May 2023 | CN¥499.2b | CN¥91.3b | CN¥18.5b | 39.4x | 27x | 5.5x |
| Wed, 19 Apr 2023 | CN¥588.7b | CN¥91.2b | CN¥19.1b | 51.9x | 30.8x | 6.5x |
Price to Earnings Ratio
30.8x
Current Industry PE
- Investors are relatively neutral on the Chinese Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 28.7x.
- The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 6.5x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 2.8% per year over the last three years, while revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 4.93% | |
| Healthcare | 0.68% | |
| Life Sciences | 5.26% | |
| Clinical Research and Equipment | 5.26% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603259 WuXi AppTec | CN¥106.33 | 6.3% +CN¥18.9b | 104.1% | PE17.8x | |
| 300347 Hangzhou Tigermed Consulting | CN¥57.86 | 4.6% +CN¥2.2b | 28.7% | PE55.7x | |
| 300759 Pharmaron Beijing | CN¥31.11 | 3.5% +CN¥1.9b | 36.4% | PE34.2x | |
| 603127 Joinn Laboratories(China)Co.Ltd | CN¥38.28 | 4.6% +CN¥1.2b | 138.8% | PE94.3x | |
| 688131 Shanghai Haoyuan Chemexpress | CN¥75.30 | 8.0% +CN¥1.2b | 105.7% | PE64.5x |